

# Tianqiang Song

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/701093/publications.pdf>

Version: 2024-02-01

43  
papers

1,372  
citations

331670

21  
h-index

361022

35  
g-index

43  
all docs

43  
docs citations

43  
times ranked

2152  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long Noncoding RNA HULC Modulates Abnormal Lipid Metabolism in Hepatoma Cells through an miR-9â€‘Mediated RXRA Signaling Pathway. <i>Cancer Research</i> , 2015, 75, 846-857.	0.9	311
2	HCC-derived exosomes elicit HCC progression and recurrence by epithelial-mesenchymal transition through MAPK/ERK signalling pathway. <i>Cell Death and Disease</i> , 2018, 9, 513.	6.3	172
3	Predictive global trends in the incidence and mortality of pancreatic cancer based on geographic location, socioâ€‘economic status, and demographic shift. <i>Journal of Surgical Oncology</i> , 2016, 114, 736-742.	1.7	59
4	Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition). <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 227-252.	1.5	55
5	Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models. <i>Journal of Hematology and Oncology</i> , 2016, 9, 20.	17.0	52
6	A supramolecular nanoparticle system based on Î²-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma. <i>Colloids and Surfaces B: Biointerfaces</i> , 2017, 155, 93-103.	5.0	48
7	Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. <i>BioScience Trends</i> , 2021, 15, 155-160.	3.4	48
8	Apatinib is effective for treatment of advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2017, 8, 105596-105605.	1.8	45
9	A single center experience of sorafenib in advanced hepatocellular carcinoma patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 1233-1238.	1.6	44
10	MiR-425-5p promotes invasion and metastasis of hepatocellular carcinoma cells through SCAI-mediated dysregulation of multiple signaling pathways. <i>Oncotarget</i> , 2017, 8, 31745-31757.	1.8	41
11	Decreased expression of acetylâ€‘CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma. <i>Cancer Science</i> , 2017, 108, 1338-1346.	3.9	36
12	Global trends in the burden of liver cancer. <i>Journal of Surgical Oncology</i> , 2017, 115, 591-602.	1.7	36
13	Changes in and challenges regarding the surgical treatment of hepatocellular carcinoma in China. <i>BioScience Trends</i> , 2021, 15, 142-147.	3.4	36
14	Recent advances in surgical treatment of hepatocellular carcinoma. <i>Drug Discoveries and Therapeutics</i> , 2015, 9, 319-330.	1.5	32
15	Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30. <i>Cancer Science</i> , 2016, 107, 507-513.	3.9	31
16	Five-CpG-based prognostic signature for predicting survival in hepatocellular carcinoma patients. <i>Cancer Biology and Medicine</i> , 2018, 15, 425.	3.0	30
17	Next-generation sequencing-guided molecular-targeted therapy and immunotherapy for biliary tract cancers. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1001-1014.	4.2	29
18	Systemic treatment of advanced or recurrent biliary tract cancer. <i>BioScience Trends</i> , 2020, 14, 328-341.	3.4	29

#	ARTICLE	IF	CITATIONS
19	The novel miR-1269b-regulated protein SVEP1 induces hepatocellular carcinoma proliferation and metastasis likely through the PI3K/Akt pathway. <i>Cell Death and Disease</i> , 2020, 11, 320.	6.3	26
20	MiR-520b suppresses proliferation of hepatoma cells through targeting ten-eleven translocation 1 (TET1) mRNA. <i>Biochemical and Biophysical Research Communications</i> , 2015, 460, 793-798.	2.1	25
21	HIF-2 $\alpha$ regulates CDCP1 to promote PKC $\delta$ -mediated migration in hepatocellular carcinoma. <i>Tumor Biology</i> , 2016, 37, 1651-1662.	1.8	25
22	Single-Cell DNA Sequencing Reveals Punctuated and Gradual Clonal Evolution in Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2022, 162, 238-252.	1.3	25
23	Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial. <i>Annals of Translational Medicine</i> , 2020, 8, 1047-1047.	1.7	23
24	Facile Fabrication of Reduction-Responsive Supramolecular Nanoassemblies for Co-delivery of Doxorubicin and Sorafenib toward Hepatoma Cells. <i>Frontiers in Pharmacology</i> , 2018, 9, 61.	3.5	21
25	Periostin mediates epithelial-mesenchymal transition through the MAPK/ERK pathway in hepatoblastoma. <i>Cancer Biology and Medicine</i> , 2019, 16, 89.	3.0	13
26	Diagnostic value of 5 serum biomarkers for hepatocellular carcinoma with different epidemiological backgrounds: A large-scale, retrospective study. <i>Cancer Biology and Medicine</i> , 2021, 18, 256-270.	3.0	13
27	Surgery for Duodenal Gastrointestinal Stromal Tumors: A Single-Center Experience. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3167-3176.	2.3	11
28	Modified Blumgart anastomosis without pancreatic duct-to-jejunum mucosa anastomosis for pancreatoduodenectomy: a feasible and safe novel technique. <i>Cancer Biology and Medicine</i> , 2018, 15, 79.	3.0	10
29	Mild chronic hypoxia-induced HIF-2 $\alpha$ interacts with c-MYC through competition with HIF-1 $\alpha$ to induce hepatocellular carcinoma cell proliferation. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 1151-1166.	4.4	9
30	Elevated serum CA19-9 indicates severe liver inflammation and worse survival after curative resection in hepatitis B-related hepatocellular carcinoma. <i>BioScience Trends</i> , 2021, 15, 397-405.	3.4	9
31	DNAJC24 is a potential therapeutic target in hepatocellular carcinoma through affecting ammonia metabolism. <i>Cell Death and Disease</i> , 2022, 13, .	6.3	6
32	Association Between Adjuvant Sorafenib and the Prognosis of Patients With Hepatocellular Carcinoma at a High Risk of Recurrence After Radical Resection. <i>Frontiers in Oncology</i> , 2021, 11, 633033.	2.8	5
33	Perioperative Enteral Nutrition Improves Postoperative Recovery for Patients with Primary Liver Cancer: A Randomized Controlled Clinical Trial. <i>Nutrition and Cancer</i> , 2021, 73, 1924-1932.	2.0	4
34	Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): A prospective, single-arm phase II trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 4073-4073.	1.6	4
35	High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma. <i>Oncology Letters</i> , 2020, 21, 69.	1.8	3
36	TALENTop: A multicenter, randomized study evaluating the efficacy and safety of hepatic resection for selected hepatocellular carcinoma with macrovascular invasion after initial atezolizumab plus bevacizumab treatment. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4175-TPS4175.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Multimarker detection of MAGE-1, MAGE-3 and AFP mRNAs by a real-time quantitative PCR assay: a possible predictor of hematogenous micrometastasis of hepatocellular carcinoma. Chinese Journal of Clinical Oncology, 2008, 5, 93-98.	0.0	1
38	Adjuvant therapy for intrahepatic carcinoma after surgical resection: chemotherapy and future perspectives. Hepatobiliary Surgery and Nutrition, 2021, 10, 878-880.	1.5	1
39	GemOX plus immune checkpoint inhibitor in combination with lenvatinib or NGS-guided targeted therapy in patients with biliary tract cancers.. Journal of Clinical Oncology, 2022, 40, e16133-e16133.	1.6	1
40	Resection of "down-staged" advanced hepatocellular carcinoma after treatment with the VEGFR2 inhibitor apatinib: five cases report. Translational Cancer Research, 2020, 9, 4999-5007.	1.0	0
41	The characterization of <i>ERBB</i> family mutations in Chinese biliary tract cancers.. Journal of Clinical Oncology, 2019, 37, e15595-e15595.	1.6	0
42	High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma. Oncology Letters, 2021, 21, 69.	1.8	0
43	Deciphering genomic characteristics of <i>ERBB</i> family members potentially involved in the recovery of anti-cancer immunity for intrahepatic cholangiocarcinoma patients.. Journal of Clinical Oncology, 2022, 40, e16003-e16003.	1.6	0